Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 10:15:1481050.
doi: 10.3389/fendo.2024.1481050. eCollection 2024.

The expression of VDACs and Bcl2 family genes in pituitary adenomas: clinical correlations and postsurgical outcomes

A N Facundo  1   2   3 , M Magalhães  3 , G C Nascimento  2   3 , R S Azulay  2   3 , R M Santos  4 , L A Freitas  4 , Agpac Nascimento  3   5 , V P Rodrigues  3   6 , W C Santos  1   3 , Amgs Beckman  3 , Jmf Abreu  2   3 , R P Silva  3 , E L Carneiro  7 , C P Oliveira Neto  2   3 , R M Gil da Costa  1   3   6 , R Corcoy  8   9 , E Mato  8   9 , M S Faria  1   2   3
Affiliations

The expression of VDACs and Bcl2 family genes in pituitary adenomas: clinical correlations and postsurgical outcomes

A N Facundo et al. Front Endocrinol (Lausanne). .

Abstract

Introduction: Pituitary adenomas (PAs) are benign tumors with high prevalence and, occasionally, aggressive course. The tumorigenesis of these lesions is not completely understood at the molecular level. BAK1 and BAX proteins play fundamental roles in apoptosis and seem to interact with VDAC proteins, whose expressions have been markedly altered in cancer, impacting their prognosis.

Objective: to evaluate the gene expression of VDAC1, VDAC2, BAK1 and BAX and their association with clinical and imaging characteristics in PA.

Methods: Clinical-epidemiological data were collected from 117 tumor samples from patients affected by PA. Invasiveness was assessed by the Knosp scale. Gene expression was examined by real-time PCR. Relative expression analysis was performed by 2^(-DDCt) method.

Results: The sample was mainly composed of women (69/117 - 57.2%). Tumor subtypes observed were Non-Functioning (NF) (73/117 - 62.4%), Acromegaly (24/117 - 20.5%) and Cushing's Disease (CD) (20/117 - 17.1%). Compared to normal tissue, there was a significant reduction in VDAC1 expression in the Acromegaly (p=0.029) and NF (p=0.002) groups. BAX expression was lower in all groups (p <0.001; p=0.007; P =0.005). No difference was found in VDAC2 and BAK1 expression, compared to normal pituitary. Overexpression of VDAC2 occurred in PAs with post-surgical regrowth (p=0.042). A strongly negative correlation was observed in BAX and BAK1 expression in CD.

Conclusion: The results indicated that downregulations of VDAC1 and BAX may be related to resistance to apoptosis. In contrast, overexpression of VDAC2 in regrowing PAs suggests an antiapoptotic role for this gene. In summary, the genes evaluated might be involved in the biopathology of PAs.

Keywords: BAK; VDAC; apoptosis; bax; pituitary adenoma; tumor regrowth.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Median (bar) and interquartile range (whiskers) of differential gene expression of VDAC1 (A). 660 VDAC2 (B). BAX (C) and BAK1 (D) according to pituitary adenoma type. 661 ACRO, acromegaly group; CUSH, Cushing’s disease group; NFU, non-functioning 662 adenoma group; One sample Wilcoxon test; ns, not significant; *P <.05. **P <.01. ****P 663 <.0001.
Figure 2
Figure 2
Matrix showing Spearman’s correlation coefficients between the relative quantifications of VDAC1 and VDAC2 gene expression in acromegaly group (A), Cushing’s disease group (B), and nonfunctioning adenoma group (C). *P <.05. **P <.017777.
See this image and copyright information in PMC

References

    1. Daly AF, Beckers A. The epidemiology of pituitary adenomas. Endocrinol Metab Clin North Am. (2020) 49:347–55. doi: 10.1016/j.ecl.2020.04.002 - DOI - PubMed
    1. Nishioka H. Aggressive pituitary tumors (PitNETs). Endocr J. (2023) 70:241–8. doi: 10.1507/endocrj.EJ23-0007 - DOI - PubMed
    1. Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G, et al. . Clinical biology of the pituitary adenoma. Endocr Rev. (2022) 43:1003–37. doi: 10.1210/endrev/bnac010 - DOI - PMC - PubMed
    1. Ng S, Messerer M, Engelhardt J, Cornelius JF, Cavallo LM, Cossu G, et al. . Aggressive pituitary neuroendocrine tumors: current practices, controversies, and perspectives, on behalf of the EANS skull base section. Acta Neurochir (Wien). (2021) 163:3131–42. doi: 10.1007/s00701-021-04953-6 - DOI - PubMed
    1. Raverot G, Ilie MD, Lasolle H, Amodru V, Trouillas J, Castinetti F, et al. . Aggressive pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol. (2021) 17:671–84. doi: 10.1038/s41574-021-00550-w - DOI - PubMed

MeSH terms